Has Valganciclovir entered medical insurance in China?

Currently, Valganciclovir (Valganciclovir) has not been included in the reimbursement list of medical insurance in China. Although this drug is already on the domestic market, patients must bear all costs themselves and cannot receive subsidies through medical insurance. According to data provided by hospitals and pharmacies, the price of domestic original drugs is about more than 10,000 yuan. This price will also fluctuate depending on the region and medical institutions.

At the same time, the overseas Indian and Turkish versions of original drugs are relatively affordable, priced at about three to four thousand yuan, and their active ingredients are exactly the same as domestic drugs. However, when purchasing overseas drugs, patients need to face multiple challenges such as transportation, customs clearance, and supplier reputation. They must ensure that the drugs they purchase are qualified and safe.

Valganciclovir plays a key role in the treatment of cytomegalovirus infection, but it has not yet been included in the medical insurance reimbursement list. This may be related to its high price, which may exceed cost-effectiveness considerations in medical insurance negotiations. The scope of reimbursement by medical insurance is usually determined based on multiple factors such as the drug's efficacy, safety, cost, and prevalence of the disease. Therefore, even though Valganciclovir (valganciclovir) has unique medical value, it is not currently covered by medical insurance due to price and other factors.

For those patients who need to continue to use Valganciclovir , full out-of-pocket payment will undoubtedly increase their financial pressure. To this end, some patients may seek other financial assistance, such as applying for drug relief funds, hospital charitable donations, or other related medical assistance projects.

In summary, although Valganciclovir is not currently covered by medical insurance, patients can still communicate with their doctors or medical units to explore whether there are other financial support methods. At the same time, it is also recommended to pay attention to the latest developments in medical insurance policies in order to understand and respond to any possible policy changes in a timely manner.